IP Library Patent Application 16875223
Patent Application
App. No. 16/875,223

COLLAGEN 7 COMPOSITIONS AND METHODS OF USING THE SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/875,223
Abstract

The present disclosure relates to compositions comprising collagen 7 and methods of using the same to treat DEB.

Claims (11)

1 . A composition comprising at least 0.5 mg/ml recombinant collagen 7 (rCo17) in a formulation comprising arginine.

2 . The composition of claim 1 , wherein rCol7 is at a concentration of about 1.0 mg/ml to about 4.0 mg/ml.

3 . The composition of claim 2 , wherein rCol7 is at a concentration of about 1.0 mg/ml to about 2.0 mg/ml.

4 . The composition of claim 3 , wherein the formulation further comprises 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose and 0.05% (v/v) polysorbate 20.

5 . The composition of claim 4 for use of medicine administered to a subject in need through infusion wherein the infusion lasts at least 60 minutes.

6 . A method for treating dystrophic epidermolysis bullosa comprising administering to a subject in need thereof an effective amount of a composition that comprises about 1.0 mg/ml to about 4.0 mg/ml recombinant collagen 7.

7 . The method of claim 6 wherein the composition is administrated to the subject in need by intravenous administration.

8 . A method for increasing closure between epidermis and dermis of the wounded skin in a subject comprising administering to the subject a composition comprising a recombinant collagen 7 in an arginine containing formulation.

9 . The method of claim 8 wherein the composition is administrated to the subject in need by intravenous administration.

10 . The method of claim 6 wherein the composition comprises about 1.0 mg/ml to about 2.0 mg/ml recombinant collagen 7.

11 . The method of claim 10 wherein the composition further comprises 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose and 0.05% (v/v) polysorbate 20.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jan 18, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
Reel/Frame 066167/0462 →
SECURITY INTEREST Recorded Nov 17, 2021
From: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058144/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: ZINSKI, JAMES
To: NOVATEC, INC.
Reel/Frame 055643/0394 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2020
From: QUINONES-GARCIA, IGOR; GUEY, LIN; LOWE, KRIS; NGUYEN, VINH; HE, BING; BANDEKAR, AMEY; BASU, SUJIT
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 052736/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2020
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: PHOENIX TISSUE REPAIR, INC.
Reel/Frame 052736/0733 →